Malignant hyperthermia (icarus syndrome): new view on the old problem
https://doi.org/10.17650/2222-8721-2014-0-1-21-29
Abstract
In the lecture shot history of research of etiology and pathogenesis of more dramatic complication of general anaesthesia – malignant hyperthermia - are presented. Importance of the interdisciplinary approach to working out of methods of preventive maintenance and treatment of it pharmacogenetics conditions in practice of the anaesthesiologist is underlined.
About the Authors
N. A. Shnayder
Prof. V.F. Voyno-Yasenetsky Krasnoyarsk State Medical University, Postgraduate Education Institute, Department of Medical Genetics and Clinical Neurophysiology
Russian Federation
Russian Federation
V. A. Shnayder
Krasnoyarsk Regional Hospital, Division of Anaesthesiology and Rheanimatology
Russian Federation
Russian Federation
References
1. Шнайдер Н.А. Злокачественная гипертермия: генетика, диагностика, профилактика. Острые и неотложные состояния в практике врача 2007;4:32–6.
2. Гринштейн А.Б., Шнайдер Н.А., Шнайдер В.А. Неврологические осложнения общей анестезии — особенности клиники, диагностики и лечения. Метод. рекомендации. Красноярск: КрасГМА, 2000.
3. Baker K.R., Landriscina D., Kartchner H., Mirkes D.M. The Icarus effect: the influenceof diluent warming on dantrolene sodium mixing time. AANA J 2007;75(2):101–6.
4. Brandom B.W. The genetics of malignant hyperthermia. Anesthesiol Clin North America 2005;23(4):615–9.
5. Dinman S. Malignant hyperthermia. Plast Surg Nurs 2006;26(4):206–7.
6. Rosenberg H., Davis M., James D. et al. Malignant hyperthermia. Orphanet J Rare Dis 2007;2:21.
7. Denborough M.A., Forster J.F., Lovell R.R. et al. Anaesthetic deaths in a family. British J Anaesth 1962;34:395–6.
8. Glahn K.P. Malignant hyperthermia. Ugeskr Laeger 2003;165(17):1763–8.
9. Шнайдер Н.А., Салмина А.Б. Неврологические осложнения общей анестезии (2-е изд., перераб. и доп.). М.: Медика, 2009. 280 с.
10. Larach M.G., Gronert G.A., Allen G.C. et al. Clinical presentation, treatment, and complications of malignant hyperthermia in North America from 1987 to 2006. Anesth Analg 2010;110(2):498–507.
11. Harrison G.G., Biebuyck J.F., Terblanche J. et al. Hyperpyrexia during anaesthesia. Br Med J 1968;3(5618):594–5.
12. Ohnishi S.T., Katsuoka M. Why does halothane relax cardiac muscle but contract malignant hyperthermic skeletal muscle? Adv Exp Med Biol 1991;301:73–87.
13. Huxley H.E. The mechanism of muscular contraction. Science 1969;164(3886):1356–65.
14. Britt B.A., Kalow W. Malignant hyperthermia: a statistical review. Can Anaesth Soc J 1970;17(4):293–315.
15. Ellis F.R., Harriman D.G., Keaney N.P. et al. Halothane-induced muscle contracture as a cause of hyperpyrexia. Br J Anaesth 1971;43(7):721–2.
16. Karan S.M., Lojeski E.W., Haynes D.H. et al. Intravenous lecithin-coated microcrystals of dantrolene are effective in the treatment of malignant hyperthermia: an investigation in rats, dogs, and swine. Anesth Analg 1996;82(4):796–802.
17. MacLennan D.H., Phillips M.S. Malignant hyperthermia. Sci 1992;256:789–94.
18. Meola G., Sansone V., Rotondo G. et al. Muscle biopsy and cell cultures: potential diagnos-tic tools in hereditary skeletal muscle channelopathies. Eur J Histochem 2003;47(1):17–28.
19. Ellis K.O., Castellion A.W., Honkomp L.J. et al. Dantrolene, a direct acting skeletal muscle relaxant. J Pharm Sci 1973;62(6):948–51.
20. Harrison G.G. Death attributable to anaesthesia. A 10-year survey (1967–1976). Br J Anaesth 1978;50(10):1041–6.
21. Gronert G.A., Milde J.H., Theye R.A. Dantrolene in porcine malignant hyperthermia. Anesthesiology 1976;44(6):488–95.
22. Kolb M.E., Horne M.L., Martz R. Dantrolene in human malignant hyperthermia. Anesthesiology 1982;56(4):254–62.
23. Picard J., Ward S., Meek T. Antidotes to anesthetic catastrophe: lipid emulsion and dantrolene. Anesth Analg 2007;105(1):283–4.
24. Zhao F., Li P., Chen S.R. et al. Dantrolene inhibition of ryanodine recep-tor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 2001;276(17):13810–6.
25. Шнайдер Н.А. Злокачественная гипертермия: лечение. Острые и неотложные состояния в практике врача 2007;5:30–3.
26. Rosenberg H., Antognini J..F., Muldoon S. Testing for malignant hyperthermia. Anesth 2002;96:232–7.
27. Ta T.A., Pessah I.N. Ryanodine receptor type 1 (RYR1) possessing malignant hyperthermia mutation R615C exhibits heightened sensitivity to dysregulation by noncoplanar 2,2',3,5',6-pentachlorobiphenyl (PCB 95). Neurotoxicology 2007;28(4):770–9.
28. Lanner J.T. Ryanodine receptor physiology and its role in disease. Adv Exp Med Biol 2012;740:217–4.
29. Hubner C.A., Jentsch T.J. Ion channel diseases. Hum Mol Gen 2002;11(20):2435–45.
30. Hudson A.J., Ebers G.C., Bulman D.E. The skeletal muscle sodium and chloride channel diseases. Brain 1995;118:547–63.
31. MacLennan D.H., Duff C., Zorzato F. et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990;343(6258): 559–61.
32. McCarthy T.V., Datar S., Mackrill J.J. Activation of ryanodine receptor/Ca2+ release channels downregulates CD38 in the Namalwa B lymphoma. FEBS Lett 2003;554(1-2):133–7.
33. MacLennan D.H., Chen S.R. Store overload-induced Ca2+ release as a triggering mechanism for CPVT and MH episodes caused by mutations in RYR and CASQ genes. J Physiol 2009;587(Pt 13):3113–5.
34. Katsuya H., Misumi M., Ohtani Y., Miike T. Postanesthetic acute renal failure due to carnitine palmityl transferase deficiency. Anesthesiol 1988;68(6):945–8.
35. Zierz S., Schmitt U. Inhibition of carnitine palmitoyltransferase by malonyl-CoA in human muscle is influenced by anesthesia. Anesthesiol 1989;70(2):373.
36. Fiege M., Wappler F., Weisshorn R. et al. In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiol 2003;98(4):944–9.
37. Fruen B.R., Mickelson J.R., Louis C.F. Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors. J Biol Chem 1997;272(43):26965–71.
38. Zhao F., Li P., Chen S.R. et al. Dantrolene inhibition of ryanodine receptor Ca2+ release channels. Molecular mechanism and isoform selectivity. J Biol Chem 2001;276(17):13810–86.
39. Jurkat R.K., Lerche H., Mitrovic N. et al. Teaching course: ion channelopathies in neurology. J Neurol 1999;46:758–63.
40. Guis S., Figarella-Branger D., Monnier N. et al. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization. Arch Neurol 2004;61:106–13.
41. Islander G., Jungner M. Anesthesia in hereditary peripheral muscular disease. Lakartidningen 2005;102(8):566–71.
42. Halsall P.J., Bridges L.R., Ellis F.R., Hopkins P.M. Should patients with central core disease be screened for malignant hyperthermia? J Neurol Neurosurg Psychiatry1996;61:119–21.
43. Jensen V. The anaesthetic management of a patient with Emery-Dreifuss muscular dystrophy. Can J Anaesth 1996;43(9):968–71.
44. Litman R.S., Rosenberg H. Malignant hyperthermia-associated diseases: State of the Art uncertainty. Anesth Analg 2009;109:1004–5.
45. Kim D.C. Malignant hyperthermia. Korean J Anesthesiol 2012;63(5):391–401.
46. Pollock N.A., Langton E.E. Management of malignant hyperthermia susceptible parturients. Anaesth Intensive Care 1997;25(4):398–407.
47. Baker K.R., Landriscina D., Kartchner H., Mirkes D.M. The Icarus effect: the influence of diluent warming on dantrolene sodium mixing time. AANA J 2007;75(2):101–6.
48. Naguib M., Flood P., McArdle J.J., Brenner H.R. Advances in neurobiology of the neuromuscular junction: implications for the anesthesiologist. Anesthesiology 2002;(96):202–31.
49. Hirshey Dirksen S.J., Larach M.G., Rosenberg H. et al. Special article: Future directions in malignant hyperthermia research and patient care Anesth Analg 2011;113(5):1108–19.
50. Stowell K.M. Malignant hyperthermia: a pharmacogenetic disorder. Pharmacogenomics 2008;9:1657–72.
Review
For citations:
Shnayder N.A., Shnayder V.A. Malignant hyperthermia (icarus syndrome): new view on the old problem. Neuromuscular Diseases. 2014;(1):21-29. (In Russ.) https://doi.org/10.17650/2222-8721-2014-0-1-21-29
Views:
1972
Email this article 